TD Cowen analyst Yaron Werber raised the firm’s price target on BioNTech to $98 from $95 and keeps a Hold rating on the shares. The firm said Q1 Comirnaty sales missed consensus but the Oncology pipeline is now primary focus with multiple ASCO updates ahead.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX: